Selumetinib CAS：606143-52-6
NAME:Selumetinib CAS：606143-52-6 MF：C17H15BrClFN4O3 MW：457.68 EINECS：207-313-3 Puiry:98%+ Appearance:White beige powder
Categories：
Life Science Chemicals
Pharmaceutical Intermediates
Email：sale06@alfachem.cn
Product introduction
| PRODUCT NAME | Selumetinib |
| CAS NO | 606143-52-6 |
| MP | >219°C (dec.) |
| Solubility | DMSO |
| DENSITY | 1.69(rough estimate) |
| STORAGE | -20°C |
| DELIVERY | 2-3DAYS |
| PACKAGE | According client's request |
Description of Selumetinib CAS：606143-52-6
Other name:
Selumetinib API
5-[(4-BroMo-2-chlorophenyl)aMino]-4-fluoro-N-(2-hydroxyethoxy)-1-Methyl-1H-benziMidazole-6-carboxaMide
Selumetinib, Free Base (AZD6244, ARRY-142886, ARRY-886, CAS 606143-52-6)
Selumetinib, also known as AZD6244 and ARRY-142886, is a highly specific mitogen-activated protein kinase 1/2 (MEK1/2) inhibitor . It is used to treat neurofibromatosis type 1 (NF1) in children 2 years of age and older who have plexiform neurofibromas that cannot be removed by surgery .
Applications of Selumetinib CAS：606143-52-6
1.Treatment of Non-Small Cell Lung Cancer (NSCLC)
Selumetinib has shown promise in overcoming resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in NSCLC.
2.Solid Tumor Management
As a selective MEK1 inhibitor, Selumetinib is being investigated for its efficacy in various solid tumors, including colorectal cancer, lung cancer, neurofibroma, and melanoma . Its role in the MAPK cascade makes it a significant agent in targeting the survival, propagation, and drug resistance of human cancers.
3.Solid Tumor Management
As a selective MEK1 inhibitor, Selumetinib is being investigated for its efficacy in various solid tumors, including colorectal cancer, lung cancer, neurofibroma, and melanoma . Its role in the MAPK cascade makes it a significant agent in targeting the survival, propagation, and drug resistance of human cancers.
4.Neurofibromatosis Type 1 (NF1)
5.Differentiated Thyroid Cancer (DTC)
Selumetinib has been granted Orphan Drug Designation in the US for the adjuvant treatment of DTC. It inhibits the MEK pathway in cancer cells to prevent tumor growth and is part of the Phase III ASTRA trial in patients with DTC who are at high risk of recurrence
Key words:
Related Products
Related Products
Inquiry
Phone/WhatsApp:
Email:
Through its excellent service and product qualities, VT Chemical has cooperated with many famous customers all over the world, eg. TCI, Covestro, etc.
HUATAO GROUP
Leave Message
SAF Coolest v1.3.1.2 设置面板 MFBSX-AJYI-DZAAE-ZAQ
无数据提示
Sorry, the current column is being updated, please look forward to it!
You can view other columns